As per the agreement, Pozen has licensed Cilag to manufacture, develop and commercialize MT 400 as migraine drug.
Pozen previously licensed US-only rights to MT 400 to GlaxoSmithKline, which markets a different dose of MT 400 as Treximet (sumatriptan and naproxen sodium).
Under the pact, Pozen is entitled to get an initial upfront payment from Cilag, followed by a milestone payment upon the approval of MT 400 by the National Health Surveillance Agency of Brazil.
Pozen executive vice president and chief commercial officer Liz Cermak said they are pleased to have reached an agreement with Cilag to develop and commercialize MT 400 in several countries in Latin America.
"In addition, the income from this deal will help fuel the development and commercialization of our integrated aspirin ‘PA’ portfolio of products," Cermak said.